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Introduction
Hepatitis C virus (HCV) has a major impact on public health, 
with around 170 million people in the world being affected1. In 
Latin America, the prevalence of hepatitis C has been esti-
mated to be at around 1.6% of the adult population, and the most 
common genotypes are 1 and 32,3. The new treatments for HCV 
include direct-acting antivirals (DAAs), which shorten length of 
therapy, improve sustained virologic response rates, and minimize 
side effects4.
Sofosbuvir is one of the most important DAAs in the market today, 
but high prices have led to a large increase in spending by health 
systems and can be a barrier to rapid global treatment, especially 
in low and middle-income countries5. The identification of global 
research on DAAs might lead to new insights into the treatments of 
HCV and suggest research directions.
Based on the above, our study aimed to identify and explore the 
worldwide development of sofosbuvir research.
Methods
We performed a bibliometric analysis using the original articles 
indexed in Web of Science. The search strategy used the follow-
ing MeSH and non-MeSH terms in the title field: Sofosbuvir, 
Sovaldi, PSI 7977, and GS 7977. The validity of the search strategy 
was tested by manually reviewing retrieved articles. Bibliometric 
indicators were investigated by analyzing annual research output, 
languages, countries, journals, authors, institutions, and citations. 
Indicators were analyzed with the option “Analyze Results” and 
“Create Citation Report” in Web of Science. Author co-citation 
analysis (ACA) was presented as network visualization map using 
VOSviewer (version 1.6.4) techniques6.
Results
A total of 341 publications for the period of 2010–2017 (up to 
March 31, 2017) were retrieved and assessed. There were a total 
of 126 journals that published research on sofosbuvir. Twenty-
four articles were economics-based. The three most prolific 
journals were Hepatology (31 articles), Gastroenterology (17), 
and Journal of Hepatology (17), responsible for 19.1% of the 
total publication output. The retrieved documents were published 
by 46 different countries. The largest contributors in absolute 
number of articles were USA (220), France (47), and Germany 
(43). Only one article was from Latin America (Brazil), and it 
was about sofosbuvir and Zika7. The total number of authors for 
all articles was 2044. John G. McHutchison from Gilead Science 
(GS) published the most documents in this field (55), followed by 
William T. Symonds from GS (30), Diana M. Brainard from GS, 
and Eric Lawitz from Texas Liver Institute/University of Texas 
Health Science Center (28). Gilead Sciences (131), Bristol Myers 
Squibb (38), and Merck (27) were the three major funders. A total 
of 86 articles were from GS, 30 from Inova Fairfax Hospital, and 
26 were from University of Texas. The sum of the citations related 
to the published articles was 10036. Average citations per item were 
29.4, with an h-index of 46.
The number of authors included in the ACA was based on a 
minimum number of fifteen articles per author. The map produced 
included 20 authors distributed into three clusters (red, blue, and 
green), as shown in Figure 1. The red cluster included eleven 
authors (headed by John G. McHutchison from GS), the blue 
cluster included five (headed by Eric Lawitz from Texas Liver 
Institute/University of Texas Health Science Center), and the 
green cluster included four authors (headed by Zoibar Younossi 
from Inova Fairfax Hospital).
Figure 1. Author co-citation analysis with VOSviewer for sofosbuvir publications. Minimum of fifteen articles per author, 20 authors were 
included.
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Dataset 1. Data obtained from Web of Science
http://dx.doi.org/10.5256/f1000research.12314.d174424
CSV contained list of studies included.
Conclusions
According to our bibliometric analysis, the study of sofosbuvir has 
been a field of intense research in the past few years. Developed 
countries have had an enormous impact on the global research in 
the field. Recently, interest has focused on the use of sofosbuvir to 
treat Zika infection, and an important contribution to the body of 
sofosbuvir research has been supported by its manufacturer. With 
continued drug development and approval of hepatitis C antivirals, 
research is expected to continue increasing.
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